Editor: What To Know
- The product is intended for surgically created osseous defects or osseous defects created from traumatic injury to the bone and has a reported healing rate of 80% at twenty-six weeks in a preclinical model1.
- GenVie™ is the first 510(k) cleared magnesium-based bone void filler in the orthopedic marketplace and is available via a private label distribution agreement with Bone Solutions Inc.
- GenVie is an injectable and moldable bone void filler with a unique combination of osteoconductive and high compression strength attributes designed to assist with bone repair and regeneration.
Today Onkos Surgical® announced the launch of GenVie ™ Magnesium Bone Scaffold, a novel biologic technology that further expands Onkos’ reach in complex limb salvage procedures. GenVie™ is the first 510(k) cleared magnesium-based bone void filler in the orthopedic marketplace and is available via a private label distribution agreement with Bone Solutions Inc. (OsteoCrete®) announced in late 2019.
GenVie is an injectable and moldable bone void filler with a unique combination of osteoconductive and high compression strength attributes designed to assist with bone repair and regeneration. The product is intended for surgically created osseous defects or osseous defects created from traumatic injury to the bone and has a reported healing rate of 80% at twenty-six weeks in a preclinical model1.
“We are excited for the launch of GenVie as this product platform provides extraordinary strength, resorption, and handling profile that our customers are looking for. GenVie provides an elegant solution for use in certain tumor and complex revision cases and compliments our focused and innovative portfolio,” said Patrick Treacy, CEO and Co-Founder of Onkos Surgical.
Onkos continues to bring to market solutions that address the clinical challenges of complex tumor and revision surgery. The addition of GenVie complements an existing portfolio and pipeline focused on personalized surgical planning, 3D printed limb salvage offerings, and 3D patient-specific joint sparing innovation. This launch signals the first of numerous product launches planned for Onkos Surgical in 2020.
